Solid-State Characterization and Dissolution Properties of Lovastatin Hydroxypropyl-β-Cyclodextrin Inclusion Complex - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Solid-State Characterization and Dissolution Properties of Lovastatin Hydroxypropyl-β-Cyclodextrin Inclusion Complex
The objectives of this study were to prepare and characterize inclusion complexes of lovastatin with hydroxypropyl-β-cyclodextrin (HPβ-CD) and to study the effect of the complexes on the dissolution rate of lovastatin (LVS). The findings suggest that LVS's poor dissolution profile can be overcome by preparing its inclusion complex with HPβ-CD.


Pharmaceutical Technology



Figure 2: The phase solubility curve of lovastatin in an aqueous solution of hydroxypropyl-β-cyclodextrin (HP-βCD) at 37 8C.
Tablets containing 10 mg of LVS were made by direct compression using various formulation excipients such as directly compressible lactose, colloidal silicon dioxide, and magnesium stearate (see Table I). Tablets equivalent to 10 mg LVS were made similarly using the kneading method, but using less lactose. The blend was compressed on an eight-station, single-rotary machine (Cadmach, India) using round-shaped, flat punches to obtain tablets of 4–7 kg/cm2 hardness and 3.5–3.7 mm thickness (see Table I). For the assay, three tablets were crushed and a blend equivalent to 10 mg of LVS was weighed and dissolved in dissolution mediums. The tablets were studied in triplicate (n = 3) for the drug-release profile using the same methodology described for the in vitro dissolution studies.

Statistical analysis. A model-independent, mathematical approach proposed by Moore and Flanner (14) for calculating f2 was used for comparison among the dissolution profiles of various samples. The f2 is a measure of similarity in the percentage dissolution between two dissolution curves and is defined by following equation:











in which n is the number of withdrawal points, Rt is the percentage dissolved of reference at the time point t, and Tt is the percentage dissolved of test at the time point t (14).

A value of 100% for f2 suggests that the test and reference profiles are identical. Values between 50 and 100 indicate that the dissolution profiles are similar, whereas smaller values imply an increase in dissimilarity between release profiles (14).

Results and discussion

Phase-solubility study. Phase-solubility analysis has been among the preliminary requirements for the optimization of the development into inclusion complexes of the drugs as it permits an evaluation of the affinity between β-CD and drug molecule in water. This process has been used by many researchers to determine the exact molar ratios in which the drugs could make complexes with β-CD (23, 24).

The solubility of LVS in water at 25 C is 0.4 g/mL; therefore, LVS can be considered a water-insoluble drug. The phase-solubility diagram of LVS in the presence of HPβ-CD was obtained by plotting the apparent equilibrium concentration of LVS against various molar concentrations of HPβ-CD (see Figure 2). This representation provides direct information about the complexation efficiency. The apparent solubility of LVS increased linearly as a function of HPβ-CD concentration over the entire concentration range studied. The solubility of LVS is increased 17.2-fold at a 14 mM/L concentration of HPβ-CD. Increased solubility may be caused by improved dissolution of LVS particles in water by HPβ-CD.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
Source: Pharmaceutical Technology,
Click here